

# 3rd Human Challenge Trials in Vaccine Development

February 6-7, 2020 - Oxford, United Kingdom

## Biosketch



**Peter JM Openshaw FMedSci**

### Professor

Imperial College London  
National Heart & Lung Institute  
Imperial College London (St. Mary's Campus)  
Norfolk Place, Paddington  
London W2 1PG  
United Kingdom  
Direct: +44 (0) 207 594 3854  
Mobile: +44 (0) 7973 820 801  
Administrator: +44 (0) 207 594 2537  
[p.openshaw@imperial.ac.uk](mailto:p.openshaw@imperial.ac.uk)

Peter Openshaw is a respiratory physician and mucosal immunologist, studying how the immune system both protects against infection but also causes disease. He has worked on RSV and influenza since the mid-1980s, leading a large Wellcome Trust funded consortium ('MOSAIC') to investigate the pathogenesis of human influenza in 2009-12. He is vice-Chair of NERVTAG, a Department of Health committee horizon-scanning for emerging respiratory threats; he directs MRC and EU-funded studies of human volunteers infected with RSV and influenza and directs HIC-Vac, an international consortium that promotes the use of human challenge to accelerate vaccine development. He is the inaugural President of the International RSV Society (under the auspices of isirv). He is Theme Lead for Infection in Imperial Biomedical Research Centre, Respiratory Infections Section Head within the National Heart and Lung Institute and Senior Consul at Imperial College London.



IABS - Rue de la Vallée, 3 - 1204 Geneva - Switzerland  
Tel : +41 22 301 10 36 - [www.iabs.org](http://www.iabs.org) - [iabs@iabs.org](mailto:iabs@iabs.org)